703 related articles for article (PubMed ID: 35089465)
1. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
2. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.
Xie L; Jiang FC; Zhang LM; He WT; Liu JH; Li MQ; Zhang X; Xing S; Guo H; Zhou P
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26712311
[TBL] [Abstract][Full Text] [Related]
3. MDSC suppresses T cell antitumor immunity in CAC via GPNMB in a MyD88-dependent manner.
Wang B; Wang L; Shang R; Xie L
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140790
[TBL] [Abstract][Full Text] [Related]
4. Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells.
Hong EH; Chang SY; Lee BR; Kim YS; Lee JM; Kang CY; Kweon MN; Ko HJ
Int J Cancer; 2013 Jun; 132(12):2839-48. PubMed ID: 23184679
[TBL] [Abstract][Full Text] [Related]
5. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
6. The Cross-talk Between Intestinal Microbiota and MDSCs Fuels Colitis-associated Cancer Development.
Ashkenazi-Preiser H; Reuven O; Uzan-Yulzari A; Komisarov S; Cirkin R; Turjeman S; Even C; Twaik N; Ben-Meir K; Mikula I; Cohen-Daniel L; Meirow Y; Pikarsky E; Louzoun Y; Koren O; Baniyash M
Cancer Res Commun; 2024 Apr; 4(4):1063-1081. PubMed ID: 38506672
[TBL] [Abstract][Full Text] [Related]
7. G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition.
Wang Y; Liu H; Zhang Z; Bian D; Shao K; Wang S; Ding Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364932
[TBL] [Abstract][Full Text] [Related]
8. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer.
Wang Y; Ding Y; Deng Y; Zheng Y; Wang S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051339
[TBL] [Abstract][Full Text] [Related]
9. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease.
Park MY; Lim BG; Kim SY; Sohn HJ; Kim S; Kim TG
Front Immunol; 2019; 10():183. PubMed ID: 30863394
[TBL] [Abstract][Full Text] [Related]
11. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3β and MyD88/NF-κB signalling pathways.
Liu JH; Chen C; Li ZY; Zou ZM; Gao DC; Zhang X; Kuang XW; Sun ZH; Zheng WJ; Zhou P; Sun SR
Exp Cell Res; 2020 Sep; 394(2):112157. PubMed ID: 32610185
[TBL] [Abstract][Full Text] [Related]
12. Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets.
Tomić S; Joksimović B; Bekić M; Vasiljević M; Milanović M; Čolić M; Vučević D
Front Immunol; 2019; 10():475. PubMed ID: 30936876
[TBL] [Abstract][Full Text] [Related]
13. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
[TBL] [Abstract][Full Text] [Related]
14. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
15. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
16. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
[TBL] [Abstract][Full Text] [Related]
17. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
18. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
19. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
Front Immunol; 2020; 11():613215. PubMed ID: 33679700
[TBL] [Abstract][Full Text] [Related]
20. MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer.
Ma N; Liu Q; Hou L; Wang Y; Liu Z
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):152-162. PubMed ID: 28534709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
